Sandoz targets more than 100 biosimilars by 2040 under its Bio100 plan and will invest $300M in a new Ljubljana drug substance plant.
LONDON — Sandoz is betting big on its newly formed biosimilar unit, as it reveals plans to grow its pipeline there by more than sevenfold and …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Sandoz bets big on biosimilars, aims to double group sales by 2035
Sandoz sets sights on 100 biosimilars in new 2040 strategy, with $300M facility build
Sandoz pretende mais que dobrar vendas até 2035
Biosimilars: Sandoz setzt sich ehrgeizige Wachstumsziele
Swiss CDMOS making moves: Lonza bets on new US facility, CordenPharma scales injectables with €80M
Swiss pharma firm Lonza to build new factory in US
Samsung Bio, waiting to break into peptides, nets $262M manufacturing deal with unnamed EU pharma
Sandoz plans to more than double annual net sales by 2035, with biosimilars leading growth. The company will expand its…
Spying a “golden decade” beyond the branded drug industry’s looming patent cliff, Sandoz is making big bets on its biosimilar…
Companhia revelou que está investindo cerca de US$ 300 milhões em uma nova fábrica de substâncias de medicamentos na Eslovênia
Der Basler Generikahersteller Sandoz setzt sich ehrgeizige Wachstumsziele. Ungelöst ist jedoch das Problem mit Trumps…
Dans les années à venir, de nombreux brevets protégeant des médicaments vont expirer. Une aubaine pour le groupe bâlois Sandoz,…
Sandoz unveiled a direct-to-consumer platform, starting off with a single medication for now as the generic drugmaker adopts a…
